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Abstract
 
Primary infection with varicella-zoster virus (VZV) causes the characteristic syndrome of varicella,
or chickenpox. Experiments in severe combined immunodeficiency mice with human skin
grafts (SCIDhu mice) indicate that VZV infection of T cells can mediate transfer of infectious
virus to skin. VZV-infected T cells reached epithelial sites of replication within 24 h after en-
tering the circulation. Memory CD4
 
 
 
 T cells were the predominant population recovered
from skin in SCIDhu mice given uninfected or infected mononuclear cells, suggesting that immune
surveillance by memory T cells may facilitate VZV transfer. The increased susceptibility of
memory T cells to VZV infection may further enhance their role in VZV pathogenesis. During
VZV skin infection, viral gene products down-regulated interferon-
 
 
 
 to permit focal replica-
tion, whereas adjacent epidermal cells mounted a potent interferon-
 
 
 
 response against cell–cell
spread. Interleukin-1
 
 
 
, although activated in VZV-infected cells, did not trigger expression of
endothelial adhesion molecules, thereby avoiding early recruitment of inflammatory cells. The
prolonged varicella incubation period appears to represent the time required for VZV to over-
come antiviral responses of epidermal cells and generate vesicles at the skin surface. Modulation
of VZV replication by cutaneous innate immunity may avoid an incapacitating infection of the
host that would limit opportunities for VZV transmission.
Key words: T cell immune surveillance • viral pathogenesis • inﬂammation • 
immune evasion • interferon-
 
 
 
Introduction
 
Varicella-zoster virus (VZV) is an alphaherpesvirus that
causes varicella (chickenpox), establishes latency in sensory
ganglia, and reactivates as zoster. Primary VZV infection
begins with respiratory mucosal inoculation, but the charac-
teristic chickenpox rash does not appear for 10–21 d (1).
Understanding initial events during human herpesvirus in-
fections is challenging because animal models are often not
available, or infection in other species may not fully repro-
duce the characteristics of human disease. In the absence of
experimental data, it has been suggested that the progression
of VZV infection during the incubation period of varicella
may resemble the stages of infection associated with the
pathogenesis of mousepox (2). According to this hypothesis,
VZV infects mononuclear cells in regional LNs, causing a
primary viremia that carries virus to reticuloendothelial organs,
such as the liver. Detection of VZV-infected mononuclear
cells in peripheral blood at the end of the incubation period
is considered to represent a secondary viremia, resulting
from viral amplification in reticuloendothelial tissues. VZV
transport to skin has been attributed to this late secondary
viremia and is presumed to be followed by the rapid appear-
ance of the classical vesicular skin rash.
VZV infects primary human T cells in vitro and exhibits
tropism for T cells in thymus/liver xenografts in our severe
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combined immunodeficiency (SCID) mouse model in vivo
(3–5). In previous experiments, we found that VZV prefer-
entially infected activated memory CD4
 
 
 
 T cells in vitro,
which are abundant in tonsillar tissues adjacent to the respi-
ratory epithelial sites of VZV inoculation (3–5). The pur-
pose of these experiments was to use SCID mice with
human skin xenografts (SCIDhu) to examine whether VZV-
infected tonsil T cells have the capacity to deliver infectious
virus from the venous circulation and cause the develop-
ment of cutaneous lesions in vivo. Since we found that
VZV was transferred to skin, the phenotypes of immune
cells recovered from skin xenografts in mice given unin-
fected and VZV-infected cells were compared. Memory
CD4
 
 
 
 T cells predominated under both conditions, sug-
gesting that these cells may be important for VZV transfer
because memory CD4
 
 
 
 T cells are inherently more likely
to traffic to skin. The contribution of memory CD4
 
 
 
 T
cells to VZV pathogenesis may be further enhanced by the
3:1 increase in VZV infectivity for this subpopulation com-
pared with naïve CD4
 
 
 
 T cells (5). Our investigations fur-
ther indicate that the pathogenesis of VZV infection during
the incubation period is modulated by potent innate im-
mune responses, especially IFN-
 
 
 
, mounted by epidermal
cells within their differentiated tissue microenvironment in
vivo. These observations suggest that viral replication in
reticuloendothelial organs, although not excluded, is not
necessary to account for the 10–21-d incubation period of
varicella. Whereas VZV spreads rapidly from cell to cell
and causes cytolysis within 24–48 h in vitro, our experi-
ments suggest that innate epidermal immune mechanisms
may prevent an incapacitating infection of the host that
would otherwise limit opportunities for VZV transmission
to other susceptible individuals.
 
Materials and Methods
 
VZV Infection of SCIDhu Mice.
 
Skin xenografts were made in
homozygous CB-17
 
scid/scid
 
 mice using human fetal tissue obtained
according to federal and state regulations; animal use was ap-
proved by the Stanford University Administrative Panel on Labo-
ratory Animal Care. Human T cells were isolated from tonsil tis-
sue, obtained according to an approved protocol, and infected by
coculture of 5–10 
 
  
 
10
 
6
 
 T cells with VZV-infected primary hu-
man lung (HEL) cells (5). Infected T cells were injected into
SCIDhu mice with skin xenografts by tail vein; xenografts were
harvested at intervals after T cell transfer and tested for infectious
virus yields and by immunohistologic analysis (5). In other exper-
iments, skin xenografts were inoculated directly with VZV-
infected HEL cells (10 
 
 
 
l) (4). To recover immune cells from
skin xenografts, tissues were minced, expressed through a 190-
 
 
 
m-pore-size sieve (Sigma-Aldrich), and centrifuged in Ficoll-
Hypaque medium (Promega, Inc.) (6). Total numbers of immune
cells were counted, and phenotypes were assessed by flow cytom-
etry using anti-CD3 (cone S4.1, IgG2a), anti-CD4 (clone 3.5,
mIgG2a), anti-CD19 (clone SJ25-C1, mIgG1), anti-CD45RA
(clone MEM56, mIgG2b) (Caltag Inc.), and anti–cutaneous lym-
phocyte antigen (CLA) (HECA-452, rat IgM; BD Biosciences).
Data for 50,000 events was collected for each marker.
Figure 1. Transfer of VZV by CD3  T cells. Column-purified CD3  T cells from tonsils were cocultured with VZV-infected HEL cells for 48 h before
i.v. transfusion into SCID mice with human skin xenografts. Skin implants were harvested at various times after T cell transfer, snapped frozen, and sec-
tioned. (A) Human fetal skin xenografts differentiated in SCID mice at 4 wk expressed human CD31 on the endothelial cells (magnification: 100 ; insert,
200 ). (B) 15–30% of tonsillar T cells used to inject SCIDhu mice expressed VZV glycoproteins as shown in a representative flow cytometric analysis.
(C) CD3  T cells were detected around hair follicles and along basement membranes 24 h after i.v. injection (left, arrows; insert, rabbit IgG control);
VZV-induced cytopathology was shown by hematoxylin and eosin (H & E) stain 21 d after T cell transfer compared with uninfected control (middle)
and by anti-VZV IgG (brown, top right; bottom right, VZV nonimmune IgG control) (magnification: left, 400 ; middle and right, 100 ). 
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Anti–IFN-
 
 
 
/
 
 
 
 Receptor Antibody Blocking.
 
Immediately after
direct inoculation of bilateral skin xenografts with VZV-infected
HEL cells, animals were given mouse mAb to human IFN-
 
   
 
receptor 
 
 
 
 chain (IFN
 
   
 
R
 
 
 
) (PBL Biomedical Laboratories) by
i.p. injection (25 
 
 
 
g). Administration of anti–IFN-
 
   
 
 receptor
antibody was maintained by s.c. delivery (50 
 
 
 
g) through an
Alzet osmotic pump (model 1007D; 0.5 
 
 
 
l/h, 7 d) (Alzet, Cu-
pertino). Skin xenografts were harvested after 7 d.
 
VZV Lesion Biopsies.
 
Punch biopsies were obtained from pa-
tients with varicella (
 
n
 
 
 
  
 
3) or zoster (
 
n
 
 
 
  
 
2) according to an ap-
proved protocol. Specimens were collected between 36–96 h af-
ter rash onset, embedded in OCT compound (TissueTec; Miles
Laboratories), frozen in isopentane, and stored at 
 
 
 
70
 
 
 
C.
 
Immunohistochemistry.
 
Formalin-fixed, paraffin-embedded skin
sections (5 
 
 
 
m) were deparaffinized, rehydrated, and treated with
antigen retrieval reagent (Vector Laboratories). Frozen sections
were fixed in 2% paraformaldehyde, treated with 1% Triton X-100
(vol/vol) and 1% sodium citrate (wt/vol), washed in TBS followed
by biotin blocking (Vector Laboratories), and treated with 3% hy-
drogen peroxidase. Primary antibodies included: anti-CD3
 
 
 
 (Ab-1,
rabbit polyclonal), anti-CD4 (clone KT69-7, mIgG1), anti-CD8
(rabbit polyclonal), anti-CD20 (Ab-1, clone L26, mIgG2a
 
 
 
), anti-
CD45RA (Ab-1, clone 111-1C5, mIgG1
 
 
 
), and anti-CD31/
PECAM (clone JC/70A, mIgG1
 
 
 
) (Lab Vision); anti-CLA (HECA-
452, rat IgM) (BD Biosciences); anti-CD45RO (clone OPD4,
mIgG1), anti–E-selectin (clone 1.2B6, mIgG1
 
 
 
), anti–intercellular
adhesion molecule (ICAM)-1 (CD54, clone 6.5B5, mIgG1
 
 
 
), and
anti–vascular adhesion molecule (VCAM)-1 (clone 1.4C2, mIgG1
 
 
 
)
(DAKO); anti–IFN-
 
 
 
 (rabbit polyclonal) (PBL Biomedical Labo-
ratories); and anti–IL-1
 
 
 
 (clone c-18, goat polyclonal), anti–TNF-
 
 
 
(clone 1E8-G6, mIgG1), and anti-pStat1 (Tyr705, rabbit poly-
clonal) (Santa Cruz Biotechnology, Inc.). Anti-CCR4 (clone 1G1,
mIgG1) mAb was a gift from David Andrew (Millennium Inc.,
Boston, MA). VZV proteins were detected with human polyclonal
anti-VZV IgG or mouse mAb to gE (gpI, mIgG2b; Chemicon).
Staining was done with biotinylated secondary antibody and HRP-
conjugated streptavidin (Lab Vision). Signals were developed with
DAB chromagen (brown) or Vector VIP (purple) and counter-
stained with hematoxylin (for DAB) or methyl green (for Vector
VIP) (Vector Laboratories).
 
Results
 
Transfer of VZV to Skin.
 
VZV-infected tonsil T cells
were given i.v. to SCID mice with human skin xenografts
that were shown to be vascularized by human CD31
 
 
 
 en-
dothelial cells (Fig. 1 A). 15–30% of CD3
 
 
 
 T cells in the
inoculum expressed VZV glycoproteins (Fig. 1 B). CD3
 
 
 
T cells were detected within the epidermis, dermis, and
around hair follicles within 24 h (Fig. 1 C, left). VZV was
recovered from skin within 7 d in three experiments. Pro-
gression to characteristic VZV lesions, with epidermal thick-
ening, cellular degeneration, and keratin disruption,
occurred in 10–21 d (Fig. 1 C, middle). Localized VZV le-
sions destroyed basement membranes and extended through
the epithelial surfaces (Fig. 1 C, right).
Since T cells were infected with VZV in vitro by cocul-
ture, some VZV-infected HEL cells might have remained
within the T cell inoculum after Ficoll gradient centrifuga-
tion and could have been a source of VZV transfer to skin
xenografts. Therefore, mice were injected with a high in-
oculum of VZV-infected HEL cells (5.0 
 
 
 
 10
 
6
 
 cells). In-
fected HEL cells did not transfer VZV to skin.
After i.v. injection of VZV-infected T cells, memory
CD45RO
 
 
 
 T cells were common in skin xenografts,
whereas no CD45RA
 
 
 
 T cells were detected in 
 
 
 
20 serial
skin sections. To further investigate these observations, pat-
terns of migration of uninfected mononuclear cells into skin
xenografts were analyzed in animals given 5.0 
 
 
 
 10
 
6
 
 cells by
tail vein infusion. Prior to transfer, the percentages of cells
that expressed CD3, CD19, or CD4/CD45RA were 88, 8,
and 31%, respectively. The total number of CD3 T cells re-
covered from skin xenografts (
 
n
 
 
 
 
 
 8) was 0.1–1.0% of the
initial i.v. inoculum. When the phenotypes of cells recov-
ered from skin xenografts at 48 h after transfer were exam-
ined, 90–96% were CD4
 
 
 
 and 97–100% were memory
CD4
 
 
 
 T cells, whereas only 0.3–0.5% expressed CD19 (Ta-
ble I). Whereas the initial percentage of naïve T cells was
31%, only 0.7–3% of CD4
 
 
 
 T cells recovered from the xe-
nografts were CD45RA
 
 
 
. These observations suggested
that memory CD4
 
 
 
 T cells predominated in skin xenografts
after the inoculation of VZV-infected mononuclear cells
because this subpopulation of immune cells had enhanced
capacity to traffic to skin independently of VZV infection.
The percentage of CLA
 
 
 
 CD4
 
 
 
 T cells recovered from skin
was also enriched from 0.7% to 1.5–3.6% after transfer of
 
Table I.
 
  Total Numbers of CD3 T Cells and Phenotypes of Uninfected Mononuclear Cells Recovered from Skin Xenografts 
after i.v. Transfer to SCIDhu Mice
 
Animal
 
a
 
CD3
 
 
 
T cells CD4
 
 
 
Naive CD4  Memory CD4  CLA
 
 
 
CD4
 
 
 
CD19
 
 
 
%% % % %
 
1 1.4 
 
 
 
 10
 
3
 
92 3.0 97 1.5 0.3
2 3.8 
 
 
 
 10
 
3
 
96 1.0 99 3.3 0.3
3 4.0 
 
 
 
 10
 
3
 
90 0 100 3.6 0.3
4 3.6 
 
 
 
 10
 
4
 
92 0.7 99.3 2.0 0.5
 
a
 
Data represent means for two xenografts from each animal; 
 
n
 
 
 
  
 
8 skin xenografts. 
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uninfected mononuclear cells but remained a relatively low
frequency subpopulation, as it was in the experiments in
which VZV-infected mononuclear cells were transferred
(Tables I and II). Based on the expected survival of 5–10%
of T cells after adoptive transfer (7), 
 
 
 
20% infection of T
cells in the inoculum and the recovery of 0.1–1.0% of T
cells from skin xenografts, we estimate that 
 
 
 
50–500 VZV-
infected T cells reach the skin xenografts in this model.
 
IL-1
 
 
 
 and IFN-
 
 
 
 Expression in Uninfected and VZV-infected
Skin Xenografts.
 
Since VZV causes rapid cytolysis of
cultured cells in vitro (1), the slow replication of VZV in
vivo suggested possible innate immune modulation. IL-1
 
 
 
was expressed constitutively in the cytoplasm of epidermal
cells in uninfected skin. In VZV-infected xenografts, IL-1
 
 
 
expression persisted and underwent nuclear translocation
within infected cells (Fig. 2, middle), although retaining its
cytoplasmic localization in uninfected cells within the epi-
dermal tissues (Fig. 2, right). TNF-
 
 
 
 was not detected in
uninfected or VZV-infected skin xenografts (not depicted).
Like IL-
 
 
 
, IFN-
 
 
 
 was expressed constitutively in unin-
fected skin cells. In VZV-infected skin xenografts, IFN-
 
 
 
was down-regulated consistently within VZV infected
cells, whereas it was expressed prominently in neighboring
uninfected epidermal cells (Fig. 3 A). Phosphorylation of
Stat 1 protein was examined to confirm this evidence of in-
hibition of the IFN-
 
 
 
 pathway in VZV-infected cells and
its activation in uninfected cells. IFN-
 
 
 
 ligation to IFN- 
receptors induces tyrosine phosphorylation of Stat1 by JAK
kinases (8). IFN-  is inhibited if Stat1 does not undergo
phosphorylation and nuclear translocation. Nuclear, phos-
phorylated Stat1 was detected in uninfected epidermal cells
near VZV-infected cells but not in cells expressing VZV
proteins (Fig. 3 B). Although IFN-  was expressed consti-
tutively, Stat1 was not phosphorylated and remained cyto-
plasmic in uninfected skin xenografts (Fig. 3 B). These ob-
servations indicated that a VZV gene product(s) blocks
Stat1 activation in order to inhibit IFN-  production in
foci of infected skin cells in vivo.
Inhibition of Type I IFN Signaling. To document the
relevance of these observations about IFN-  and Stat1
phosphorylation to VZV pathogenesis, skin xenografts in
five mice (n   10 xenografts) were inoculated with VZV
and mice were given neutralizing antibody against the
IFN- /  receptor, which blocks type I IFN activity (9).
Four skin xenografts were harvested from mice in the anti-
body-treated and control groups 7 d after VZV inoculation
for viral titrations. The titer of infectious VZV was 10-fold
higher in skin from antibody-treated animals (Fig. 4 E).
VZV was recovered from all xenografts from mice given
Table II.  Identification of Mononuclear Cell Populations 
in VZV-infected Skin Specimens 
Type of skin
Surface markers expressed
by infiltrating cells 
VZV-infected
skin xenografts
VZV patient
skin biopsies
CD20 –  
CD3   
CD4   
CD8   
CD45RA –  
CD45RO   
CLA  ,  1%  
CCR4 –  
Results represent cell phenotypes observed in at least three frozen
sections from the same skin xenograft or VZV patient lesion biopsy
specimen upon testing with each of the markers listed. –, not detected;
 , abundantly present.
Figure 2. IL-1  expression in VZV-infected and uninfected epidermal cells. In this representative figure, formalin-fixed, paraffin-embedded sections
of VZV-infected skin xenografts were stained with anti-VZV IgG, detected with DAB chromagen (brown) as shown in the left panel (magnification,
100 ). Serial sections of these samples were stained with anti–IL-1  and detected with DAB as illustrated in the middle and right panels (magnification,
630 ). IL-1  expression was analyzed in cells expressing VZV proteins as shown within the area outlined in the left panel and in neighboring uninfected
epidermal cells in the same section. IL-1  was activated and translocated to the nuclei of VZV infected cells (middle) but showed a diffuse cytoplasmic
stain in neighboring uninfected cells (right).Ku et al. 921
anti–IFN- /  receptor antibody compared with three of
four xenografts from controls. In the other xenografts ex-
amined by immunohistochemistry, diminished IFN signal-
ing was shown to result in substantially larger cutaneous le-
sions (Fig. 4, C and D). Stat1 was activated and localized to
nuclei of neighboring uninfected cells in control animals
(Fig. 4 A). Phosphorylated Stat1 was detected in some cells,
primarily at the margins of VZV lesions, in mice given
anti–IFN-    receptor (Fig. 4 B).
Migration of Mononuclear Cells into VZV-infected Skin. In
these experiments, one of two bilateral skin xenografts was
inoculated with VZV-infected HEL cells and the other
with uninfected fibroblasts. 10 d later, uninfected mononu-
clear cells were injected i.v., and skin xenografts were har-
vested after 24–48 h. Mononuclear cells within VZV-
infected skin xenografts expressed CD3, whereas no
CD20  B cells were detected in three experiments (Table
II). CD4  and CD8  T cells were distributed uniformly
with no evidence of increased numbers near VZV lesions.
Infiltrating cells were exclusively CD45RO  T cells (Table
II). T cells expressing CLA were detected at low frequen-
cies ( 1%), but CCR4  T cells were not identified. Total
numbers of T cells recovered from VZV-infected skin
were slightly higher than corresponding uninfected xe-
nografts, but surface marker profiles were comparable by
flow cytometry. The relative percentages of subpopulations
were as observed when uninfected mononuclear cells were
transferred (Table I). Thus, T cell migration into skin was
not influenced by VZV protein expression or cellular pro-
teins, IL-1  or IFN- , in the absence of other signals.
The analysis of lesion biopsies from VZV-infected pa-
tients showed many infiltrating mononuclear cells, most of
which expressed CD4 or CD8; a few CD20  B cells and
IFN- –expressing cells, probably macrophages, were also
detected (Table II). CD45RO  memory T cells, naive
CD45RA  T cells, and CLA  and CCR4  T cells were
present in comparable numbers (Table II). The differences
in cell profiles between VZV lesion biopsies and VZV-
infected skin xenografts after adoptive transfer suggested
that recruitment and/or retention of skin homing T cells,
naïve T cells, B cells, and macrophages required host im-
mune-mediated signals.
Expression of Endothelial Cell Adhesion Molecules. Since
skin homing of memory T cells is regulated by adhesion
molecules and chemoattractant receptors (10), adhesion
molecule expression was examined to explain differences
between T cell subpopulations detected in biopsies of VZV
lesions and VZV-infected skin xenografts. Expression of
E-selectin, ICAM-1, or VCAM-1 by endothelial cells was
not detected in VZV-infected skin xenografts, indicating
that VZV replication, which is associated with the expres-
sion of all kinetic classes of viral proteins, and altered IL-1 
Figure 3. IFN-  expression and Stat1 phosphorylation in VZV-infected and uninfected epidermal cells. Formalin- fixed, paraffin-embedded sections
of VZV-infected skin xenografts were pretreated and double stained with anti-VZV IgG, detected with DAB (brown), and anti–IFN-  or anti-pStat1
antibody detected with Vector VIP (purple). Sections are shown at magnification 200 . (A) Infected cells were identified by VZV protein (brown) ex-
pression. In double labeled skin sections, IFN-  (purple) expression was prominent in adjacent uninfected cells but not in VZV-infected cells (top) compared
with sections stained with rabbit IgG as a control for IFN-  (bottom). (B) In double labeled sections, phosphorylated Stat1 (purple) was up-regulated in
adjacent uninfected cells but absent in VZV-infected cells (top); pStat1 was not detected in uninfected skin (bottom right) compared with rabbit IgG
control stain (bottom left).T Cell Tropism and Innate Immunity in VZV Pathogenesis 922
and IFN-  expression alone did not induce adhesion mole-
cules (Fig. 5, left). In contrast, all adhesion molecules were
expressed extensively in VZV lesion biopsies when host
cellular immunity was intact (Fig. 5, right).
Discussion
Although the signs and symptoms of infections caused by
human herpesviruses are well documented, much less is
known about critical events in pathogenesis that precede the
onset of the clinical illness. These experiments using the
SCIDhu mouse model of VZV pathogenesis provide evi-
dence that infectious VZV can be transferred by T cells
through the circulation to sites of replication in skin, result-
ing in the formation of typical cutaneous lesions. The obser-
vations suggest that VZV tropism for T cells, which has been
shown in vitro and in T cell xenografts in SCIDhu mice,
contributes to the pathogenesis of primary VZV infection in
vivo (3–5). The adoptive transfer of uninfected and VZV-
infected human mononuclear cells was associated with en-
richment of memory CD4  T cells within human skin
xenografts in the SCIDhu mouse model. Therefore, we sug-
gest that VZV tropism for T cells permits the virus to take
advantage of the usual pathways for T cell migration
through skin during immune surveillance. Whereas naïve T
cells enter LNs through the high endothelial venules, exit
through efferent lymphatics, and return to the blood, mem-
ory T cells traffic through skin and other tissues. In our ex-
periments, the percentage of naïve CD4  T cells recovered
from skin xenografts was only 0.7–3% compared with
 30% in the infused population. In previous work, we re-
ported that VZV preferentially infects memory T cells com-
pared with naïve CD4  T cells at a ratio of 3:1 in vitro (5).
Lymphoid tissues of the upper respiratory tract, including
tonsils and adenoids, contain activated, memory T cells,
which may become infected when VZV infects respiratory
mucosa. Together, these observations suggest that two fac-
tors, which are the intrinsic propensity of memory CD4  T
cells to migrate into skin tissue and the enhanced susceptibil-
ity of memory CD4  T cells to VZV infection, may com-
bine to create an important role for memory CD4  T cells
in VZV pathogenesis. Thus, memory CD4  T cells that be-
come infected at sites of respiratory epithelial inoculation
may be more likely to deliver VZV to epidermal cells and
initiate the cutaneous phase of infection than other circulat-
ing cells of the immune system, such as naïve CD4  T cells.
As a clinical correlate, VZV dissemination to skin may be
modulated in young children, who have few memory T
cells, whereas adults with varicella who have  75% memory
CD4  T cells usually develop many cutaneous lesions (1).
Memory T cells that express CLA or CCR4 are targeted
to skin through interactions with adhesion molecules and
chemoattracts when inflammation is triggered (11). We de-
tected a two- to fivefold enrichment of CLA  CD4  T
Figure 4. Blocking of IFN-  signaling enhanced VZV replication in skin. Skin xenografts were infected with VZV by direct inoculation in mice
treated with anti-IFN   R  antibody or controls and harvested at day 7 after infection. Half of the skin implant was fixed in 4% paraformaldehyde for
histological analysis, and the other half was disassociated into cell suspension to measure virus titers by infectious focus assay. (A and B) Shown are repre-
sentative results from skin sections examined at 7 d (large arrow, VZV lesion); phosphorylated Stat1 (purple; small arrow) was translocated to nuclei in ad-
jacent cells but not within VZV lesions (magnification, 200 ). (C and D) Skin lesions shown by staining with anti-VZV IgG (purple) were larger at day
7 in animals given anti-IFN   R  antibody (right) than controls (left) (magnification, 100 ). (E) Mean VZV titers in four skin xenografts from two
mice were 10-fold higher in anti-IFN   R  antibody-treated animals compared with controls (P   0.05, unpaired t test).Ku et al. 923
cells in skin when SCIDhu mice were given uninfected
human mononuclear cells, but the percentage remained
 3.6 of CD4  T cells. We did not demonstrate any in-
crease in the numbers of CLA  or CCR4  CD4 T cells in
skin after the adoptive transfer of VZV-infected T cells.
These observations suggest that VZV pathogenesis does not
depend on a selective infection of memory CD4  T cell
subpopulations that express specific skin homing markers.
Since the epidermis should be in its resting state during the
initial transfer of VZV to skin by infected T cells, traffick-
ing of CLA  or CCR4  T cells should not be selectively
involved in the initial phase of VZV pathogenesis. A sec-
ond clinical correlate is that skin trauma, such as sunburn
acquired during the incubation period, is associated with a
much more severe varicella rash. Under such conditions,
the twofold increase in infectivity of VZV for CLA  T
cells that we observed in vitro, combined with the in-
creased migration of these cells to damaged skin, could fa-
cilitate more efficient transfer of VZV to the epidermis.
The down-regulation of MHC class I molecules that we
have observed on VZV-infected T cells may also contrib-
ute to successful VZV transport to skin (12).
VZV transmission to other susceptible individuals re-
quires enough replication to create lesions that contain in-
fectious virus at the skin surface (Fig. 6). However, cell–cell
spread in vivo at the rate characteristic of VZV replication
in human fibroblasts in vitro would be life threatening to
the host and would therefore diminish opportunities for
person-to-person transmission. Examining VZV lesion for-
mation in parallel with innate antiviral responses in skin xe-
nografts in vivo showed IFN-  down-regulation in VZV-
infected cells and no induction of adhesion molecules on
capillary endothelial cells. These conditions favor the patho-
gen during the early phase of skin infection. At the same
time, IFN-  production by epidermal cells adjacent to
VZV-infected cells appears to provide an innate barrier
against aggressive spread of VZV from cell to cell in skin.
Our analysis of IFN-  and IL-1  in VZV-infected and
uninfected skin xenografts revealed a subtle interaction be-
Figure 5. Expression of adhesion molecules by cutaneous endothelial
cells in VZV-infected skin xenografts and biopsies of VZV skin lesions.
Serial frozen sections of VZV-infected skin xenografts (left) or lesion biopsies
from patients with varicella or herpes zoster (right) were stained with anti-
bodies against adhesion molecules expressed by endothelial cells. Signals
were detected with Vector VIP (purple) and counterstained with methyl
green. Representative results from one of three VZV-infected skin xenografts
and one of five VZV lesion biopsies are shown for expression of CD31,
E-selectin, ICAM-1, and VCAM-1. E-selectin, ICAM-1, and VCAM-1
were highly expressed by CD31-positive dermal endothelial cells in patient
lesion biopsies but were not detected in VZV infected skin xenografts (aster-
isk, VZV skin lesion). Magnification, 100 .
Figure 6. A model of the pathogenesis of primary VZV infection. T
cells within the local lymphoid tissue of the respiratory tract may become
infected by transfer of VZV from its initial site of inoculation in respiratory
epithelial cells. T cells may then transport the virus to the skin immediately
and release infectious VZV. The remainder of the 10–21-d incubation
period appears to be the interval required for VZV to overcome the innate
IFN-  response in enough epidermal cells to create the typical vesicular
lesions containing cell-free virus at the skin surface. The signaling of en-
hanced IFN-  production in adjacent skin cells may prevent a rapid, un-
controlled cell–cell spread of VZV. Secondary “crops” of varicella lesions
may result when T cells traffic through early stage cutaneous lesions become
infected and produce a secondary viremia. Intact host immune responses
appear to be required to trigger up-regulation of adhesion molecules, facilitat-
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tween VZV and epidermal cell cytokine responses. Type I
interferons, IFN- , and to a lesser extent, IFN- , are the
predominant mediators of innate antiviral activity. Constitu-
tive IFN- /  expression occurs in some cells or tissues, al-
lowing an immediate antiviral response (13). IFN- /  acti-
vation is induced by the Jak/Stat pathway when ligands bind
to IFN- /  receptors and stimulate transcription of the IFN
regulatory factors (IRFs) (8). IRF3 and IRF7 are crucial for
maximal expression of IFN- /  (14, 15). Constitutive IFN-
 /  signaling is thought to sustain IRF7 expression and en-
hance IFN- /  production in a positive feedback loop in
response to viral infection (16). Most viruses have mecha-
nisms to inhibit synthesis of IFNs or evade downstream anti-
viral effects in order to allow viral spread before adaptive im-
munity develops. HSV, a human alphaherpesvirus closely
related to VZV, has several such mechanisms (17).
We found that IFN-  was expressed constitutively in the
epidermis, independently of Stat1 activation in uninfected
skin xenografts. After VZV infection, IFN-  expression was
down-regulated in VZV-infected cells concurrently with in-
hibition of Stat1 phosphorylation. In contrast, Stat1 was
phosphorylated and translocated to nuclei, accompanied by
IFN-  up-regulation in neighboring, uninfected cells. The
capacity of VZV to block IFN-  in some cells enables the
virus to replicate, spread from cell to cell, and create focal
cutaneous lesions, whereas IFN-  activation protects the ad-
jacent cells. Blocking the IFN- /  receptor enhanced VZV
replication and lesion formation in vivo, showing that these
patterns of IFN-  expression and Jak/Stat signaling have bi-
ological importance for regulating VZV pathogenesis. Ex-
periments are in progress to identify VZV proteins that have
the capacity to disrupt the IFN-  pathway. Overall, the in-
nate IFN-  response appears to modulate VZV growth,
providing a substantial barrier against cell–cell spread in skin
during the prolonged varicella incubation period. Our ob-
servations suggest that VZV gradually overcomes this barrier
in order to form polykaryocytes, eventually creating a vesic-
ular lesion that penetrates the skin surface (Fig. 6).
IL-1  is synthesized constitutively and stored in supra-
basal layers of the epidermis as a 31-kD precursor molecule,
pre–IL-1  (18, 19). When cells die, pre–IL-1  is released
and cleaved into a 17-kD IL-1  molecule by extracellular
proteases. IL-1  can also be released by the calcium-depen-
dent cysteine proteases called calpains, which are ubiqui-
tously but weakly expressed in all cell types (20). Mature
IL-1  displaces the IL-1 receptor antagonist and binds to
IL-1 R. Internalization and accumulation of the IL-1 –IL-1
receptor complex in the nucleus induces genes involved in
skin cell proliferation and other inflammatory changes (21,
22). We found that IL-1  was expressed constitutively in
skin but remained in the cytoplasm of uninfected cells adja-
cent to and distant from VZV lesions. In contrast, IL-1  ac-
cumulated in nuclei of VZV-infected cells. This pattern
suggests that IL-1  is activated directly or indirectly by
VZV replication within epidermal cells. However, IL-1  is
apparently not released, or its release into the local skin
microenvironment fails to trigger IL-1  activation or en-
hanced IL-1  production by neighboring cells.
Expression of cellular adhesion molecules on endothelial
cells increases the efficiency of T cell trafficking. Their ex-
pression can be regulated by inflammatory cytokines such
as IL-1 , TNF- , and IFN- , which were produced by
cells infected with some viral pathogens (23–26). In our
experiments, VZV-infected T cells migrated into skin and
released infectious virus for entry into and replication in
epidermal and dermal cells without preexisting expression
of E-selectin, ICAM-1, or VCAM-1 on endothelial cells,
and without eliciting the expression of these inflammatory
proteins. Although IL-1  was activated in VZV-infected
cells, it remained cytoplasmic in uninfected cells and did
not have the capacity to induce adhesion molecules on en-
dothelial cells in skin xenografts. VZV replication did not
induce TNF-  production by skin cells. In contrast, wide-
spread expression of E-selectin, ICAM-1, and VCAM-1 by
endothelial cells was observed in biopsies of clinical VZV
lesions. CLA  T cells were enriched in lesion biopsies
compared with VZV-infected skin xenografts, which is
consistent with a requirement for host immune mecha-
nisms to up-regulate adhesion molecules. This comparative
analysis indicated that endothelial cell activation was not
stimulated by VZV gene products alone, despite their ex-
tensive expression during lytic infection of epidermal and
dermal cells, but required host immune mechanisms.
Infectious VZV can be recovered from peripheral blood
mononuclear cells during the last few days of the incuba-
tion period of varicella in the healthy host and for 2–3 d af-
ter the rash appears. We speculate that this secondary vire-
mia results from infection of migrating T cells by virus
produced in lesions that are not yet visible at the skin sur-
face (Fig. 6). This hypothesis is suggested by our finding
that many T cells entered VZV-infected skin xenografts af-
ter adoptive transfer. Thus, viral amplification could result
from progressive VZV infection in skin without requiring a
phase of replication in reticuloendothelial tissues during the
incubation period. Our experiments do not exclude some
VZV replication in liver or other reticuloendothelial or-
gans, which might contribute to pathogenesis by increasing
the viral load. However, our data indicate that the interval
required for VZV to overcome innate immune barriers in
skin is sufficient to account for the prolonged incubation
period. Continued VZV replication in skin would also be
predicted to sustain the viremia associated with malignant
varicella, which leads to pneumonia, hepatitis, and enceph-
alitis in immunocompromised children who fail to develop
VZV-specific adaptive immunity (1). Further, the transfer
of VZV from infected epidermal cells into migratory T
cells may also explain how VZV causes viremia and dissem-
ination in high-risk patients with herpes zoster.
Based on these SCIDhu mouse experiments, we offer a
new paradigm of primary VZV infection which suggests
new directions for the analysis of events in VZV pathogen-
esis. According to this model, infectious VZV is transferred
to skin shortly after inoculation of the respiratory mucosa.
Although other cell types may be involved, memory CD4 
T cells play a prominent role in this process because of their
intrinsic pattern of skin trafficking and their increased sus-Ku et al. 925
ceptibility to VZV infection. VZV gene products modulate
innate epidermal cell defenses, down-regulating IFN-  to
ensure localized replication in skin. Epidermal cell infection
appears to occur without activating endothelial cell adhe-
sion molecules, thereby delaying the invasion of antiviral
inflammatory cells at the early stage of cutaneous lesion for-
mation. At the same time, uninfected epidermal cells are
signaled to mount a potent innate IFN-  response, which
counters an overly aggressive cell–cell spread in skin (Fig.
6). This model helps to explain how VZV replication may
be restricted by the host even though VZV-specific T cell
immunity is not detected until after the appearance of ve-
sicular skin lesions (1). Acquisition of T cells that recognize
VZV proteins correlates with cessation of skin replication,
which we suggest is necessary to stop continued, secondary
T cell viremia. A benign infectious process during the ini-
tial phase of VZV pathogenesis and a circumscribed clinical
illness provides the optimal strategy for VZV to be sus-
tained within the human population (27).
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